XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
P/E ratio for XOMA Corporation (XOMA)
P/E ratio as of 2023: -5.20
According to XOMA Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.20. At the end of 2022 the company had a P/E ratio of -12.28.
P/E ratio history for XOMA Corporation from 1985 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.20 |
| 2022 | -12.28 |
| 2021 | 14.90 |
| 2020 | 35.42 |
| 2019 | -31.08 |
| 2018 | -7.94 |
| 2017 | 18.58 |
| 2016 | -0.47 |
| 2015 | -7.60 |
| 2014 | -10.07 |
| 2013 | -4.71 |
| 2012 | -2.18 |
| 2011 | -1.11 |
| 2010 | -1.39 |
| 2009 | 209.51 |
| 2008 | -1.82 |
| 2007 | -35.19 |
| 2006 | -4.07 |
| 2005 | 49.60 |
| 2004 | -2.78 |
| 2003 | -8.45 |
| 2002 | -8.95 |
| 2001 | -23.94 |
| 2000 | -19.25 |
| 1999 | -3.45 |
| 1998 | -2.90 |
| 1997 | -13.92 |
| 1996 | -5.72 |
| 1995 | -4.21 |
| 1994 | -1.70 |
| 1993 | -3.60 |
| 1992 | -4.38 |
| 1991 | -11.86 |
| 1990 | -12.20 |
| 1989 | -16.52 |
| 1988 | -11.83 |
| 1987 | -21.36 |
| 1986 | -1.87 |
| 1985 | -29.82 |